“Pivotal repeat-dose toxicity studies were conducted in rats (dermal), dogs (subcutaneous), and minipigs (dermal).”
✓ VerifiedFDA multi-discipline review, p. 49Source ↗
Why that species
Dog the most appropriate species for coverage of the major human metabolites
“The dog is the most appropriate animal species for the major metabolites.”
✓ VerifiedFDA multi-discipline review, p. 64Source ↗
Surrogate molecule
No surrogate; the clinical compound was tested
“In nonclinical studies, OPA-15406 and OPC-271 were used as codenames for difamilast.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Species: general tox
Rat (dermal), dog (subcutaneous) and minipig (dermal)
“Pivotal repeat-dose toxicity studies were conducted in rats (dermal), dogs (subcutaneous), and minipigs (dermal).”
✓ VerifiedFDA multi-discipline review, p. 49Source ↗
Species: DART
Rat (fertility, EFD, pre/postnatal) and rabbit (EFD)
“a fertility and early embryonic development study in rats, two embryofetal development studies in rats and rabbits, a prenatal and postnatal development study in rats, and two juvenile animal toxicity studies in rats.”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗
Species: carcinogenicity
Rat and mouse (2-year dermal)
“In 2-year dermal carcinogenicity studies in rats and mice, no test article-related neoplastic findings were observed in rats or mice that received difamilast at dermal doses up to 3% (3.7 to 10 times the MRHD based on AUC comparison).”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗
Surrogate used in
No surrogate used; difamilast (OPA-15406/OPC-271) tested directly
“In nonclinical studies, OPA-15406 and OPC-271 were used as codenames for difamilast.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗